Popular Articles
Natural Remedies

Clotting In Veins Close To Skin May Be Associated With More Dangerous Deep-Vein Blood Clots
About one-fourth of patients with superficial vein thrombosis-clotting in blood vessels close to the skin-also may have the life-threatening condition deep vein thrombosis, according to a report in the July issue of Archives of Dermatology, one of the JAMA/Archives journals.
generic viagra online
First Ten-Year Follow-Up Shows That Treatment With AVONEX® Leads To Long-Term Benefits In Early Multiple Sclerosis Patients
Biogen Idec (NASDAQ: BIIB) announced data results from the CHAMPIONS (Controlled High-Risk AVONEX® (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study In Ongoing Neurologic Surveillance) study, an open label follow-up to CHAMPS (Controlled High Risk Subjects AVONEX MS Prevention Study). Based on the CHAMPS study, AVONEX was granted approval for use in patients who experienced their first clinical MS episode with MRI findings. The CHAMPIONS ten-year follow up showed that patients treated immediately after their first episode had significantly less chance of experiencing a second attack versus those patients with delayed treatment. These results at ten years also indicate that 80 percent of patients taking AVONEX were below an expanded disability status scale (EDSS) score of three. These data were presented as a poster at the Annual American Academy of Neurology (AAN) meeting.
News of the day
Study Finds New Approach To Treating Heart Attacks Reduces Risk Of Life-Threatening Complications
Transferring heart attack patients to specialized hospitals to undergo angioplasty within six hours after receiving clot-busting drugs reduces the risk of life-threatening complications, according to a Canadian-led study published today. The findings, published in the New England Journal of Medicine, suggest that routine early transfer of patients after clot-busting drugs are administered results in significantly better outcomes than the current practice of transferring patients only when the clot-busting drugs fail.
Health Insurance

Centers For Medicare & Medicaid Services Recognizes The Joint Commission's Critical Access Hospital Accreditation

The Department of Health and Human Services" Centers for Medicare & Medicaid Services (CMS) has again granted The Joint Commission deeming authority for the accreditation of critical access hospitals. The CMS designation means that critical access hospitals accredited by The Joint Commission may choose to be "deemed" as meeting Medicare and Medicaid certification requirements. CMS found that The Joint Commission"s standards for critical access hospitals meet or exceed those established by the Medicare and Medicaid program. CMS" notice of approval is effective through November 21, 2011. "Critical access hospitals are an important safety net, providing Medicare beneficiaries living in rural areas with the care that they need," says Mark Pelletier, R.N., M.S., executive director, Accreditation and Certification Services, The Joint Commission. "The Joint Commission is pleased to collaborate with CMS to provide quality oversight for these important providers of rural health care." Critical access hospitals have no more than 25 acute care beds and have an average length of stay of no more than 96 hours. These hospitals, which are typically located more than 35 miles from another hospital, receive cost-based reimbursement from Medicare. Accreditation is voluntary and seeking deemed status through accreditation is an option, not a requirement. Organizations seeking Medicare approval may choose to be surveyed either by an accrediting body, such as The Joint Commission, or by state surveyors on behalf of CMS. All deemed status surveys are unannounced. In addition to critical access hospitals, The Joint Commission has federal deeming authority for ambulatory surgery centers, durable medical equipment suppliers, home health, hospice, hospitals and laboratories. The Joint Commission


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):